Literature DB >> 1517907

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

L Navas1, E Wang, V de Carvalho, J Robinson.   

Abstract

PURPOSE: To determine the outcomes in children at high risk for death or complications from respiratory disease who are hospitalized with respiratory syncytial virus (RSV) infection.
DESIGN: Retrospective chart review.
SETTING: Twelve pediatric tertiary care centers. PATIENTS: All hospitalized children with an RSV infection diagnosed by a positive antigen detection test result or viral isolation during the study period from 1988 to 1991, encompassing three winter seasons. Charts from patients in the following high-risk groups were reviewed in detail: (1) congenital heart disease, (2) chronic lung disease, (3) immunodeficiency, (4) age less than 6 weeks, (5) gestational age less than 36 weeks, and (6) hypoxia (defined as oxygen saturation less than 90% or arterial oxygen pressure less than 60 mm Hg). MEASUREMENTS: The age of all children, the date of RSV identification, and the use of oxygen supplementation, intensive care, and ventilatory support. In addition, the duration of these treatments and the duration of hospitalization were noted. Left-to-right shunting and pulmonary hypertension before RSV infection were determined in those children with congenital heart disease. The nature of the chronic lung disease was noted. Death within 2 weeks of RSV identification was recorded, and the use of ribavirin, bronchodilators, and corticosteroids was determined.
RESULTS: Significant year-to-year variation in the frequency of RSV infection was confirmed, with a peak during the 1989-1990 winter noted by the majority of centers (p = 0.0001). Of the 1584 patients in the study, 260 had underlying cardiac disease, 200 had chronic lung disease, 35 had compromised immune function, 378 had been premature, 373 were less than 6 weeks of age, and 338 had hypoxia. Seventeen patients died within 2 weeks (mortality rate 1%); significantly more patients with underlying cardiac disease (3.4%) or lung disease (3.5%) died. Immunocompromised patients had the longest hospital stay (median 39 days), followed by those patients with underlying cardiac or pulmonary disease (11 days); patients less than 6 weeks of age (5 days) and those with hypoxia (6 days) had the shortest hospital stays. Patients with underlying cardiac and pulmonary disease also required oxygen supplementation for a significantly longer period.
CONCLUSION: The year-to-year variation in frequency of RSV infection was confirmed in this study. Morbidity and mortality rates associated with RSV infection in a high-risk population in Canada were significantly lower than previously reported.

Entities:  

Mesh:

Year:  1992        PMID: 1517907     DOI: 10.1016/s0022-3476(05)90000-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  60 in total

Review 1.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

2.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

3.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

4.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

5.  Use of palivizumab in children with congenital heart disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

6.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

Review 7.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 8.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

9.  New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.

Authors:  Dai Kimura; Jordy Saravia; Sridhar Jaligama; Isabella McNamara; Luan D Vu; Ryan D Sullivan; Salvatore Mancarella; Dahui You; Stephania A Cormier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

Review 10.  Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis.

Authors:  Caroline Davison; Kathleen M Ventre; Marco Luchetti; Adrienne G Randolph
Journal:  Pediatr Crit Care Med       Date:  2004-09       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.